GERON CORP
GERN · XNASCIK 886744fmd_0A5DHFEHZDDDHZE9B62MSJMCEXManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2009 to Sep 30, 2026, 67 periods
Latest annual · FY2023
Millions- Total revenues
- 0
- Operating income
- (69)
- Net income
- (84)
- Free cash flow
- (219)
Latest quarter · Q3 FY2026
Millions- Total revenues
- 60
- Operating income
- 6
- Net income
- 1
Daily close · GERNIEX trades only
Nov 13, 2025 to Nov 11, 2026 · 250 sessions1.00 USD
Built from trades executed at IEX only, one exchange with a small share of US volume. This is not the consolidated tape. The close is the last IEX trade of the session, not the official closing price. Earlier sessions are divided by the later split ratios the API confirmed against IEX prices; dividends are not adjusted. Switch to As traded for the prices as they printed. End of day, not real time: a session is published the day after it trades.
Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use. iex.io/legal/hist-data-terms
Key stats
Open AnalysisCompound annual growth
- Revenue, 3 yearsFY2020 to FY2023
- -2.2%
- Net income, 5 yearsFY2020 to FY2025
- n/m
GERON CORP (GERN) financials: quick answers
Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.
| Metric | FY2025 | FY2024 | Change | Source |
|---|---|---|---|---|
| Operating income | -$68.6 million | -$173.7 million | 10-K 2026-03-02 · proof | |
| Net income | -$83.5 million | -$174.6 million | 10-K 2026-03-02 · proof | |
| Cash from operating activities | -$111 million | -$218.6 million | 10-K 2026-03-02 · proof | |
| Total assets | $570.5 million | $593.8 million | -3.9% | 10-K 2026-03-02 · proof |
| Total liabilities | $344.7 million | $313.5 million | +10% | 10-K 2026-03-02 · proof |
| Cash and cash equivalents | $77.6 million | $79 million | -1.8% | 10-K 2026-03-02 · proof |
- What was GERON CORP (GERN)'s operating income in fiscal 2025?
- GERON CORP (GERN) reported operating income of -$68.6 million for fiscal 2025 (the year ended Dec 31, 2025), against -$173.7 million the year before. Source: the 10-K filed with the SEC on Mar 2, 2026. SEC
- What was GERON CORP (GERN)'s net income in fiscal 2025?
- GERON CORP (GERN) reported net income of -$83.5 million for fiscal 2025 (the year ended Dec 31, 2025), against -$174.6 million the year before. Source: the 10-K filed with the SEC on Mar 2, 2026. SEC
- What was GERON CORP (GERN)'s cash from operating activities in fiscal 2025?
- GERON CORP (GERN) reported cash from operating activities of -$111 million for fiscal 2025 (the year ended Dec 31, 2025), against -$218.6 million the year before. Source: the 10-K filed with the SEC on Mar 2, 2026. SEC
- What are GERON CORP (GERN)'s total assets?
- As of Dec 31, 2025, GERON CORP (GERN) reported total assets of $570.5 million, against $593.8 million a year earlier (-3.9%). Source: the 10-K filed with the SEC on Mar 2, 2026. SEC
- What are GERON CORP (GERN)'s total liabilities?
- As of Dec 31, 2025, GERON CORP (GERN) reported total liabilities of $344.7 million, against $313.5 million a year earlier (+10%). Source: the 10-K filed with the SEC on Mar 2, 2026. SEC
- What are GERON CORP (GERN)'s cash and cash equivalents?
- As of Dec 31, 2025, GERON CORP (GERN) reported cash and cash equivalents of $77.6 million, against $79 million a year earlier (-1.8%). Source: the 10-K filed with the SEC on Mar 2, 2026. SEC
Read from the FinancialMD API on Nov 13, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.
The same numbers for an agent, with proof on every value:
curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=ticker:GERN&period_type=annual&limit=5"Information only, not investment advice.